Abeona therapeutics announces acceptance of late-breaker abstracts highlighting new clinical data for novel aav-based gene therapies in mps iiia and mps iiib at worldsymposium™

New york and cleveland, dec. 21, 2020 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced that abstracts detailing new interim results from its abo-102 phase 1/2 transpher a study for mps iiia and abo-101 phase 1/2 transpher b study for mps iiib have been accepted for platform oral presentations during the late-breaking abstract session at the 17th annual worldsymposium™ being held february 8-12, 2021.
ABEO Ratings Summary
ABEO Quant Ranking